Mina Kim, Acelyrin CEO
January 6, 2025 04:30 PM ESTUpdated January 7, 07:12 AM
R&D

Up­dat­ed: Ace­lyrin’s stock drops due to mixed Phase 2 da­ta in thy­roid eye dis­ease

Ayisha Sharma

News Reporter

Ace­lyrin has of­fered a more de­tailed look at mid-stage re­sults for its thy­roid eye dis­ease drug can­di­date as it tees up its next de­vel­op­ment steps …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Vir’s ear­ly T cell en­gager da­ta of­fer first look at can­cer piv­ot, stock jumps

Up­dat­ed: Gala­pa­gos to split in­to two com­pa­nies, slash head­count as it eyes turn­around

ARCH, F-Prime and Mubadala pump $200M in­to for­mer De­nali pro­grams

Every FDA drug ap­proval from 2024: Few­er nods, but long-await­ed treat­ments cross the fin­ish line

Sana’s stock soars on new cell ther­a­py da­ta; UniQure’s $75M of­fer­ing

Maze files for first biotech IPO of 2025, fol­low­ing $115M fund­ing boost

A service from the Financial Times